Peau Hormonale sans alcool
Food supplement declared in France, declaration No 2022-7-1094, decision dated 19 July 2022
Peau Hormonale sans alcool (Curanderas) is a food supplement declared in France. Status: déclaré en France, commercialisation possible : l'administration ne s'est pas opposée à la déclaration (ce n'est ni une autorisation ni une évaluation de sécurité). 2 rules of use apply to its ingredients (limits and warnings).
- Brand
- Curanderas
- Food business operator placing the product on the market
- CURANDERAS
- Status
- Déclaré en France, commercialisation possible : l'administration ne s'est pas opposée à la déclaration (ce n'est ni une autorisation ni une évaluation de sécurité)
- Form
- Compte-gouttes
- Daily dose
- 3 ml
- Directions for use
- 90 gouttes par jour (3ml) diluées dans une boisson (eau,jus...).
- Intended populations
- Adolescents de 11 à 17 ans, Femme
- Not recommended for (according to the manufacturer)
- Femmes allaitantes, Enfants (moins de 12 ans), Enfants en bas âge (1 à 3 ans), Femmes enceintes, Nourrissons (moins de 1 an), Sous antidiabétiques, Enfants (de moins de 6 ans), Enfants (de moins de 10 ans)
- Objectives stated by the manufacturer (these are not authorised claims)
- Cycles féminins, Peau
Declaration 322811, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 23 October 2026.
Regulatory points
- Conditions légales
Serenoa repens (W.Bartram) Small: L'étiquetage doit comporter une mention recommandant de prendre conseil auprès d'un professionnel de santé ("Demander l'avis de votre médecin et /ou pharmacien").
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
- Conditions légales
Vitex agnus-castus L.: L'étiquetage doit comporter un avertissement déconseillant l'usage chez les femmes ayant des antécédents personnels ou familiaux de cancer du sein.
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
Declared composition
Plants
| Plant | Part | Preparation | Per day |
|---|---|---|---|
| Serenoa repens (W.Bartram) Small | Fruit | Extrait fluide hydroglycériné | 150 mg |
| Marsdenia sylvestris (Retz.) P.I.Forst. | Feuille | Extrait fluide hydroglycériné | 120 mg |
| Withania somnifera (L.) Dunal | Racine | Extrait fluide hydroglycériné | 90 mg |
| Mahonia aquifolium (Pursh) Nutt. | Racine | Extrait fluide hydroglycériné | 90 mg |
| Vitex agnus-castus L. | Feuille | Extrait fluide hydroglycériné | 90 mg |
| Taraxacum campylodes G.E.Haglund | Racine | Extrait fluide hydroglycériné | 60 mg |
List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).
Label warnings
Ce produit n'est pas un médicament.A utiliser dans le cadre d’un régime alimentaire varié, équilibré, et d’un mode de vie sain. Ne pas dépasser la dose journalière recommandée. Tenir hors de portée des enfants. A conserver dans un endroit frais et sec à l'abri de la lumière.Déconseillé aux enfants de moins de 12 ans, aux femmes enceintes et allaitantes et aux personnes sous traitement anti-diabétique. Demander conseil auprès d'un professionnel de la santé.
This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Serenoa repens (W.Bartram) Small
Read the warning, when it applies and the studies cited
SAW PALMETTO – SERENOA REPENS
Route of administration: Oral
Cautions and warnings
Condition of application: All subpopulations.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Condition of application: Adult males only.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use to exclude a diagnosis of prostate cancer (USP-NF 2024; Mills and Bone 2005).
2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Condition of application: Adult females only.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking oral contraceptives or hormone replacement therapy (UpToDate 2024).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Contraindications
Condition of application: Adult females only.
Do not use if you are pregnant, breastfeeding, or attempting to conceive (UpToDate 2024).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
- Withania somnifera (L.) Dunal
Read the warning, when it applies and the studies cited
ASHWAGANDHA - WITHANIA SOMNIFERA
Route of administration: Oral
Cautions and warnings
Condition of application: General debility; Memory enhancement; Adaptogen; Restlessness/nervousness.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Upton 2000; McGuffin et al. 1997).
2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
When using this product exercise caution if you drive or use machinery as you may experience drowsiness (Berardi et al. 2002).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
- Vitex agnus-castus L.
Read the warning, when it applies and the studies cited
CHASTE TREE - VITEX AGNUS-CASTUS
Route of administration: Oral (WHO 2009; Bradley 2006; Mills and Bone 2000)
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking hormone-containing medications such as progesterone preparations, oral contraceptives or hormone replacement therapy (Brinker 2010; WHO 2009; Bradley 2006).
3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Contraindications
Do not use if you are pregnant, breastfeeding or attempting to conceive unless you have consulted with a health care practitioner/health care provider/health care professional/doctor/physician (EMA 2018; Najib et al. 2022; Brinker 2010; WHO 2009; Dugoua et al. 2008; ESCOP 2003; Blumenthal 2000; Mills and Bone 2000).
8 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
- Taraxacum campylodes G.E.Haglund
Read the warning, when it applies and the studies cited
DANDELION - TARAXACUM OFFICINALE
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a liver or biliary disorder or an intestinal obstruction (Brinker 2010; Godfrey et al. 2010; ESCOP 2003; Bradley 1992).
4 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Condition of application: Constipation, Flushing of the urinary tract, Indigestion, and Loss of appetite.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Contraindications
Applies to products providing 10 g or more of dried leaf or dried root or dried whole plant, per day or 10 mL or more of juice, per day.
Do not use if you have diabetes or a blood pressure, kidney or cardiovascular disorder (Goksu et al. 2010; EMA 2009; Hunt et al. 2005; Green et al. 2002; Mujais and Katz 2000; Carlsen et al. 1990; Kuller et al. 1986; Artz et al. 1966).
8 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Do not use if you are taking heart medications or other products containing diuretics (Goksu et al. 2010; EMA 2009; Hunt et al. 2005; Green et al. 2002; Mujais and Katz 2000; Carlsen et al. 1990; Kuller et al. 1986; Artz et al. 1966).
8 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
They concern the ingredient, not this product or its dose. They do not replace medical advice.
Brand : Curanderas
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.